🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› UK
Clinical trial register · United Kingdom · industry-sponsored

Industry-sponsored studies with a UK investigative site

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2847 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Sep 2026, 03:15 UTC
2847
Studies in scope
industry-sponsored, all four open statuses
1382
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2004 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 416
Narrow the register
Recruitment status
Phase
Lead sponsor
AstraZeneca195 Merck Sharp & Dohme LLC116 Hoffmann-La Roche105 Novartis Pharmaceuticals97 Janssen Research & Development, LLC93
Site city
London2004 Manchester672 Birmingham470 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
2847 of 2847 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
NCT03754790Hemophilia
Genzyme, a Sanofi Company
Phase 3
281
London, Glasgow
2019-01-09
Active, closed
A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve
NCT03682536Myelodysplastic Syndromes
Celgene
Phase 3
363
Aberdeen, Bournemouth, Headington, Oxford, Lincoln, London, Manchester
2019-01-02
Active, closed
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,882
Luton, Glasgow, Sheffield, London, Oxford
2018-12-28
Active, closed
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
NCT03725059Breast Cancer
Merck Sharp & Dohme LLC
Phase 3
1,240
Bristol, Nottingham, Colchester, London, Solihull, Truro
2018-12-27
Active, closed
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT03734029Breast Cancer
Daiichi Sankyo
Phase 3
557
Truro, London, Edinburgh, Nottingham, Guildford
2018-12-27
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
NCT03711032High-risk Non-muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC
Phase 3
1,397
Inverness, London
2018-12-24
Active, closed
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
NCT03742102Triple Negative Breast Neoplasms
AstraZeneca
Phase 1/2
243
Cambridge, London, Manchester, Oxford
2018-12-21
Active, closed
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
NCT03775486Non-small Cell Lung Cancer NSCLC
AstraZeneca
Phase 2
401
Dundee, Hull
2018-12-21
Active, closed
A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease
NCT03737214Fabry Disease
Idorsia Pharmaceuticals Ltd.
Phase 3
107
London, Manchester
2018-12-18
Active, closed
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
NCT03765918Head and Neck Neoplasms
Merck Sharp & Dohme LLC
Phase 3
714
Cambridge, Cottingham-Hull, London, Sheffield
2018-12-17
Active, closed
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
NCT03614260Hypertension, Vascular Diseases, Cardiovascular Diseases
ReCor Medical, Inc.
Not applicable
225
Basildon, Bournemouth, Canterbury, Cardiff, London, Newcastle upon Tyne
2018-12-14
Active, closed
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
NCT03742895Advanced Solid Neoplasms
Merck Sharp & Dohme LLC
Phase 2
329
Oxford, Manchester, Newcastle upon Tyne, Sheffield
2018-12-12
Active, closed
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
NCT03762850Immunoglobulin A Nephropathy
Travere Therapeutics, Inc.
Phase 3
406
Reading, Cambridge, Middlesbrough, Derby, Brighton, London, Manchester, Salford
2018-12-11
Active, closed
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
NCT03701334Early Breast Cancer
Novartis Pharmaceuticals
Phase 3
5,101
Truro, Sutton, Cardiff, London, Nottingham, Oxford, Preston, Stoke-on-Trent
2018-12-07
Active, closed
Post-Authorization Long-Term Safety Study of LUTATHERA
NCT03691064Neuroendocrine Tumors
Advanced Accelerator Applications
Observational
1,014
Birmingham, Cambridge, Glasgow, Liverpool, London, Manchester, Sheffield
2018-11-28
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 3
507
Bristol, Cardiff, London
2018-11-28
Active, closed
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
NCT03732677Muscle Invasive Bladder Cancer
AstraZeneca
Phase 3
1,063
Edinburgh, London, Metropolitan Borough of Wirral, Nottingham, Sheffield
2018-11-16
Active, closed
Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS
NCT03802799Fragile X Syndrome
Zynerba Pharmaceuticals, Inc.
Phase 2/3
476
Leicester, Edinburgh, Manchester
2018-11-09
Active, closed
Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"
NCT03588299Hemophilia A
Bayer
Phase 1/2
11
Manchester
2018-11-07
Recruiting
Developing Protocols for Modelling of Genetic Diseases Using Induced Pluripotent Stem Cells
NCT03612310Genetic Disease
Sapna Vyas
Observational
3,000
Edinburgh
2018-11-01
Active, closed
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
NCT03732820Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Phase 3
895
Guildford, Manchester, Sheffield, Southampton, Swansea
2018-10-31
Active, closed
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
NCT03539744Multiple Myeloma
AbbVie
Phase 3
265
Cambridge, London, Norwich, Nottingham, Glasgow, Stoke-on-Trent, Manchester, Portsmouth
2018-10-22
Active, closed
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
NCT03616587ER+ HER2- Advanced Breast Cancer
AstraZeneca
Phase 1
396
Cambridge, Leeds, London, Manchester, Sutton
2018-10-11
Active, closed
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
NCT03602859Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Tesaro, Inc.
Phase 3
1,400
Glasgow, Metropolitan Borough of Wirral, Portsmouth, Sutton, Truro
2018-10-11
Active, closed
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
NCT03539536Non-small Cell Lung Cancer
AbbVie
Phase 2
270
London, Nottingham, Oxford, Birmingham
2018-10-10
Recruiting
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933Ewing Sarcoma, Colorectal Adenocarcinoma
Inhibrx Biosciences, Inc
Phase 1
411
London, Manchester
2018-10-08
Active, closed
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
NCT03690388Differentiated Thyroid Cancer
Exelixis
Phase 3
187
Birmingham, Bristol, London, Oxford, Aberdeen, Glasgow, Cardiff, Manchester
2018-10-05
By invitation
Adverse Event Data Collection From External Registries on Nonacog Beta Pegol
NCT03690336Haemophilia B
Novo Nordisk A/S
Observational
10
Sheffield
2018-10-01
Active, closed
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT03703297Small Cell Lung Cancer
AstraZeneca
Phase 3
730
Manchester, Truro
2018-09-27
Active, closed
Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
NCT03326336Non-syndromic Retinitis Pigmentosa
GenSight Biologics
Phase 1/2
10
London
2018-09-26
Active, closed
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
NCT03671018B-cell Non-Hodgkin Lymphoma
Hoffmann-La Roche
Phase 1/2
422
Cambridge, Plymouth
2018-09-25
Recruiting
Extension Study for the Port Delivery System With Ranibizumab (Portal)
NCT03683251Neovascular Age-Related Macular Degeneration
Hoffmann-La Roche
Phase 3
1,000
Bristol, Liverpool, London, Newcastle upon Tyne, Sunderland, Wolverhampton
2018-09-20
Active, closed
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
NCT03553836Melanoma
Merck Sharp & Dohme LLC
Phase 3
976
Cambridge, London, Sutton, Manchester
2018-09-12
Active, closed
Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency
NCT03636438Ornithine Transcarbamylase (OTC) Deficiency
Ultragenyx Pharmaceutical Inc
Observational
11
Birmingham
2018-08-30
Active, closed
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
NCT03398135Ulcerative Colitis (UC)
AbbVie
Phase 3
1,242
Cambridge, Exeter, Edinburgh, London, Southampton, Barnsley, Liverpool, Newcastle upon Tyne
2018-08-28
Recruiting
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873Solid Tumors, Hematologic Malignancies
Merck Sharp & Dohme LLC
Phase 3
3,500
Aberdeen, Cambridge, Edinburgh, Manchester, Sheffield, Broomfield, Glasgow, Preston
2018-08-21
Active, closed
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
NCT03456076Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche
Phase 3
257
London, Manchester
2018-08-16
Active, closed
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
NCT03547973Metastatic Urothelial Cancer
Gilead Sciences
Phase 2
502
Birmingham, London, Northwood, Surrey
2018-08-13
Recruiting
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
NCT02991469Juvenile Idiopathic Arthritis
Sanofi
Phase 2
51
London, Leeds, Liverpool
2018-08-09
Active, closed
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
NCT03529110Breast Cancer
Daiichi Sankyo
Phase 3
524
Exeter, Aberdeen, London, Manchester, Edinburgh, Nottingham, Guildford
2018-08-09
Active, closed
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03568318Atopic Dermatitis
AbbVie
Phase 3
1,533
London, Oxford, Dundee, Glasgow, Leeds
2018-08-09
By invitation
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
NCT03628612Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric
Autolus Limited
Phase 2
500
Glasgow, London, Manchester, Newcastle upon Tyne
2018-08-02
Active, closed
A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
NCT03492177Pulmonary Arterial Hypertension
Actelion
Phase 2
63
London
2018-07-23
Recruiting
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796Neoplasms
Celgene
Phase 2/3
1,541
Leeds, London, Manchester Withington, Shirley Southampton
2018-07-19
Active, closed
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945Ulcerative Colitis
Eli Lilly and Company
Phase 3
1,058
Bury, London, Oxford
2018-07-18
Recruiting
A Multicenter Patient Registry on Outcomes From Cryoanalgesia of the Intercostal Nerves
NCT05110989Post Operative Pain
AtriCure, Inc.
Observational
5,000
Leicester
2018-06-29
Active, closed
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
NCT03625037DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL
Genmab
Phase 1/2
666
Manchester, Plymouth, Southampton, Sutton
2018-06-26
Active, closed
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
350
London, Sutton
2018-06-25
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 3
565
Aberdeen, London, Sutton, Cambridge, Coventry, Dundee, Leeds, Manchester
2018-06-21
Active, closed
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
NCT03755791Hepatocellular Carcinoma
Exelixis
Phase 3
837
Bristol, Cambridge, London, Manchester, Belfast
2018-06-10
Active, closed
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
NCT03448042Solid Tumors
Genentech, Inc.
Phase 1
123
Oxford
2018-06-06
Recruiting
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT03564340Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer
Regeneron Pharmaceuticals
Phase 1/2
890
Oxford, Sutton, London, Manchester
2018-05-21
Active, closed
Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices
NCT03366545Heart Failure
Biotronik SE & Co. KG
Observational
3,030
Chertsey, Dudley, Kettering
2018-05-14
Active, closed
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed
pharmaand GmbH
Phase 3
1,097
Canterbury, Cliftonville, Brighton, Bristol, Cambridge, Edinburgh, Lancaster, Leeds
2018-05-14
Active, closed
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
NCT03528694Non-muscle-invasive Bladder Cancer
AstraZeneca
Phase 3
1,018
Birmingham, Glasgow, Guildford, London, Sheffield, Southampton, Taunton
2018-05-14
Active, closed
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT03533283Non-Hodgkins Lymphoma
Hoffmann-La Roche
Phase 1/2
211
Leicester, London, Newcastle upon Tyne
2018-05-08
Active, closed
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
GlaxoSmithKline
Phase 2
237
Airdrie, Bristol, Cardiff, London, Oxford
2018-05-03
Active, closed
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
NCT03401788VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation, VHL Syndrome, VHL Gene Inactivation
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
50
Cambridge
2018-05-02
Recruiting
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Merus B.V.
Phase 1/2
560
Cambridge, London
2018-05-02
Active, closed
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT03425643Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
797
Leicester, Metropolitan Borough of Wirral, London, Sutton, Nottingham, Birmingham, Newcastle upon Tyne, Plymouth
2018-04-24
Active, closed
Pyruvate Kinase Deficiency Global Longitudinal Registry
NCT03481738Pyruvate Kinase Deficiency
Agios Pharmaceuticals, Inc.
Observational
500
London, Newcastle upon Tyne
2018-04-23
Active, closed
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
NCT03383458Hepatocellular Carcinoma, Liver Cancer
Bristol-Myers Squibb
Phase 3
545
London, Manchester, Metropolitan Borough of Wirral
2018-04-18
Active, closed
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT03462719Leukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC
Phase 3
211
Birmingham, Cambridge, Charterhouse Square, Glasgow, Leeds, Plymouth, Romford, Sheffield
2018-04-17
Active, closed
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
NCT03466411Crohn's Disease
Janssen Research & Development, LLC
Phase 2/3
1,409
Barnsley, Cambridge, London
2018-04-13
Active, closed
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma
NCT03470922Melanoma
Bristol-Myers Squibb
Phase 2/3
714
Bristol, Glasgow, Swansea, London, Inverness
2018-04-11
By invitation
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
NCT03391778Neoplasms
USWM CT, LLC
Phase 1
250
London, Manchester, Sutton
2018-04-09
Active, closed
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
NCT03105102Crohn's Disease
AbbVie
Phase 3
1,336
Cambridge, Exeter, Hull, Edinburgh, Glasgow, London, Manchester, Oxford
2018-04-09
Active, closed
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
NCT03407144Hodgkin Lymphoma
Merck Sharp & Dohme LLC
Phase 2
340
London
2018-04-09
Active, closed
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
NCT03473743Urothelial Carcinoma
Janssen Research & Development, LLC
Phase 1/2
125
Lancaster, London, Nottingham
2018-04-05
Active, closed
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
NCT03363373Neuroblastoma
Y-mAbs Therapeutics
Phase 2
122
Glasgow, Leeds, Southampton
2018-04-03
Active, closed
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
NCT03423628Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
AstraZeneca
Phase 1
159
Cambridge, Glasgow, Leeds
2018-04-02
Recruiting
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT03424005Metastatic Breast Cancer
Hoffmann-La Roche
Phase 1/2
1,132
Glasgow, London
2018-03-30
Active, closed
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
NCT03390504Urothelial Cancer
Janssen Research & Development, LLC
Phase 3
629
Bristol, London, Manchester, Plymouth, Sheffield, Southampton, Sutton
2018-03-23
Active, closed
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
NCT03345823Crohn's Disease
AbbVie
Phase 3
747
Bath, Warrington, London, Taunton, Prescot, Belfast, Birmingham, Dudley
2018-03-21
Active, closed
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
NCT03436485Prostate Cancer Metastatic
Orion Corporation, Orion Pharma
Phase 1/2
204
Bedlington, Cardiff, Glasgow, Liverpool, London, Manchester, Preston
2018-03-19
Active, closed
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
NCT03330847Metastatic Triple Negative Breast Cancer
AstraZeneca
Phase 2
273
Aberdeen, Bristol, Cardiff, Durham, Edinburgh, Leicester, London, Manchester
2018-03-07
Active, closed
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT03431350Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC
Phase 2
136
Bath, London, Southampton, Sutton, Truro
2018-03-02
Recruiting
Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
NCT03695978Haemophilia A
Octapharma
Observational
200
Headington, Birmingham, London, Newcastle upon Tyne
2018-02-13
Active, closed
ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease
NCT03319485Parkinson Disease
InSightec
Not applicable
92
London
2018-02-09
Active, closed
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
NCT03328273Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 1
12
Birmingham, Bournemouth, Cardiff, Leeds, London, Nottingham, Oxford, Southampton
2018-01-31
Active, closed
AMPLATZER PFO Occluder Post Approval Study
NCT03309332Stroke, Patent Foramen Ovale
Abbott Medical Devices
Not applicable
1,214
London
2018-01-31
Active, closed
Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients
NCT02922036Heart Failure
EBR Systems, Inc.
Not applicable
300
Liverpool, London, Manchester, Middlesbrough, Oxford
2018-01-17
By invitation
A Safety Surveillance Study in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy
NCT03167203Macular Degenerative Disease
Astellas Institute for Regenerative Medicine
Phase 1/2
36
London
2018-01-08
Active, closed
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
NCT03386513Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
AbbVie
Phase 1/2
179
Oxford
2018-01-02
Recruiting
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
NCT03142152Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency, Heart Diseases
Cardiac Dimensions, Inc.
Not applicable
300
Leeds
2018-01-01
Recruiting
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
NCT03394365Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
Pierre Fabre Medicament
Phase 3
115
Birmingham, London
2017-12-29
Active, closed
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
NCT03319940Small Cell Lung Carcinoma
Amgen
Phase 1
269
Manchester
2017-12-26
Active, closed
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
NCT03395197mCRPC
Pfizer
Phase 3
1,054
Plymouth, Oxford, Glasgow, Bebington, Cornwall, Liverpool, London
2017-12-18
Recruiting
A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.
NCT03320304Treatment Resistant Depression
LivaNova
Observational
500
Leicester, London, Newcastle upon Tyne, Wells
2017-12-14
Active, closed
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
NCT03424018Achondroplasia
BioMarin Pharmaceutical
Phase 3
119
London, Sheffield
2017-12-12
Active, closed
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
NCT03301506Primary Biliary Cirrhosis
Gilead Sciences
Phase 3
340
Birmingham, Hull, London, Newcastle upon Tyne, Nottingham, Plymouth, Portsmouth
2017-12-12
Active, closed
A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
NCT03332797Breast Cancer
Genentech, Inc.
Phase 1
181
London, Suttton
2017-11-24
Active, closed
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
NCT03336333Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeiGene
Phase 3
590
Birmingham, Bournemouth, Cambridge, Canterbury, Greater Manchester, Leeds, London, Maidstone
2017-10-31
Active, closed
Endurant CHevAr New Indication Trial: ENCHANT
NCT03320252AAA - Abdominal Aortic Aneurysm
Medtronic Cardiovascular
Observational
150
London, Manchester
2017-10-26
Active, closed
A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis
NCT03218488Psoriasis
Janssen-Cilag International NV
Observational
135
Cardiff, London, Salford
2017-10-25
Recruiting
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
NCT03373968Duchenne Muscular Dystrophy
Italfarmaco
Phase 2/3
206
Liverpool, Gobowen, London, Newcastle upon Tyne
2017-10-24
Active, closed
A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa
NCT03019406Glycogen Storage Disease Type II-Pompe's Disease
Genzyme, a Sanofi Company
Phase 2
22
London, Manchester
2017-10-12
Active, closed
Anatomical Shoulder Domelock System Study
NCT03312465Avascular Necrosis, Revision Surgery, Conditions Consequent to Earlier Operations, Arthritis, Rheumatoid
Zimmer Biomet
Observational
73
Derby
2017-09-28
Recruiting
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer
Apollomics Inc.
Phase 2
497
London, Manchester, Surrey Quays
2017-09-27
Active, closed
H1 Hip Resurfacing Arthroplasty
NCT03326804Hip Osteoarthritis, Hip Necrosis, Hip Dysplasia
Embody Orthopaedic Limited
Observational
250
London
2017-09-26
Rows per page Showing 2601–2700 of 2847
Previous 25 26 27 28 29 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-uk?page=27

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.